Aviir Inc., Launches Complete Cardiovascular Genetic Testing
Comprehensive menu provides crucial information about inherited cardiovascular testing to individuals and families
IRVINE, Calif., May 8, 2013 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced that it will be extending its offered services with comprehensive inherited cardiovascular disease genetic test menu.
The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for testing in both individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.
"Aviir's mission is to identify and prevent cardiovascular diseases, and subsequent deaths, through the best diagnostic means available," said Doug Harrington, M.D., CEO of Aviir. "To this end we've added a comprehensive list of inherited cardiovascular disease testing to our menu. This type of testing can be the difference between effective disease management and needless risk of sudden cardiac death. The novel approach Aviir has taken to identify disease-causing genetic variants allows for not only an unprecedented level of thoroughness (ie. 100% coverage of the disease-causing genes), but also for unmatched speed in returning results to physicians and patients."
Genetic testing can help determine a successful course of treatment for the patient, as well as identify any familial testing needs resulting from a positive result. In many instances the first indication that an individual is affected is sudden cardiac death, hence, testing is key to preventing a catastrophic event. This information can lead a patient to make successful lifestyle changes and pursue therapy to live a healthy and successful life despite the disease.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Aviir Inc., also offers testing across the molecular genetic spectrum, including pharmacogenetics, Leiden factor, and ApoE testing. Please visit www.aviir.com for more information.
Life Capital Partners
For media inquiries, please contact:
Tamara York Public Relations, LLC
SOURCE Aviir Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.